Background: Sepsis, a life-threatening condition characterized by a dysregulated immune response to infection, remains a significant clinical challenge globally. This study aims to enhance the predictive accuracy of existing sepsis severity scores by developing augmented versions of the SOFA and SAPS-III models, termed Pro-SOFA and Pro-SAPS, through the integration of biomarkers procalcitonin (PCT), neutrophil-tolymphocyte ratio (NLR), and C-reactive protein (CRP). Methods: This prospective observational study was conducted in the medical ICU of a tertiary care hospital in southern India from August 2022 to December 2023. A total of 301 adult patients suspected or confirmed to have sepsis were assessed for eligibility, with 171 patients completing the study. Demographic and clinical data were collected; SOFA and SAPS-III scores were calculated and augmented with PCT, NLR, and CRP to develop Pro-SOFA and Pro-SAPS models. The performance of these models was evaluated using Brier scores, AUC, and net reclassification index (NRI). Results: The augmented Pro-SOFA and Pro-SAPS models demonstrated superior predictive accuracy compared to their original counterparts. The Brier scores for Pro-SOFA and Pro-SAPS were 0.181 and 0.165, respectively, indicating better calibration than the original scores. The Pro- SAPS showed significant improvement over the original SAPS-III score (NRI = 0.50, SE = 0.14, p < 0.01). Similarly, Pro-SOFA outperformed the original SOFA (NRI = 0.49, SE = 0.13, p < 0.01). Conclusion and clinical significance: Integrating PCT, CRP, and NLR with SOFA and SAPS-III scores to develop Pro-SOFA and Pro-SAPS significantly improves the predictive accuracy for sepsis mortality and can thus potentially improve sepsis outcomes.
15 March 2025 in Computers in Biology and Medicine
Antibiotic allergy labels (AALs) are common and often incorrect. They have many potential impacts, including the use of broader‐spectrum antibiotics and suboptimal treatment of infections. The impact of inaccurate allergy labels on post‐transplant outcomes in the solid organ transplant population is not well described. We performed a retrospective review of 2,373 consecutive solid organ transplants occurring between 2011 and 2021, to analyze the impact of AALs, specifically penicillin, on outcomes in the first year after transplantation. Three hundred and twenty‐two patients (13.6%) had a penicillin allergy label, while 572 patients (24%) had at least one antibiotic allergy label. Patients with a penicillin allergy label were more likely to have a positive Clostridioides difficile test ( p = 0.021). Patients with allergy labels also had significantly more utilization of alternative antimicrobial agents ( p < 0.001) and longer inpatient hospital durations ( p = 0.013). This study suggests that AALs may be a risk factor for inferior outcomes after solid organ transplantation and could represent a modifiable target for pre‐transplant optimization.
Antibiotic allergy labels (AALs) are common and often incorrect. They have many potential impacts, including the use of broader-spectrum antibiotics and suboptimal treatment of infections. The impact of inaccurate allergy labels on post-transplant outcomes in the solid organ transplant population is not well described. We performed a retrospective review of 2,373 consecutive solid organ transplants occurring between 2011 and 2021, to analyze the impact of AALs, specifically penicillin, on outcomes in the first year after transplantation. Three hundred and twenty-two patients (13.6%) had a penicillin allergy label, while 572 patients (24%) had at least one antibiotic allergy label. Patients with a penicillin allergy label were more likely to have a positive Clostridioides difficile test (p = 0.021). Patients with allergy labels also had significantly more utilization of alternative antimicrobial agents (p < 0.001) and longer inpatient hospital durations (p = 0.013). This study suggests that AALs may be a risk factor for inferior outcomes after solid organ transplantation and could represent a modifiable target for pre-transplant optimization.